

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

J774A1

RRID:CVCL_0358

Type: Cell Line

Proper Citation

CLS Cat# 400220, RRID:CVCL_0358

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0358

Proper Citation: CLS Cat# 400220, RRID:CVCL_0358

Description: Cell line J774A1 is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Female

Disease: Mouse reticulum cell sarcoma

Comments: Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: J774A1

Synonyms: J-774A.1, J774.A1, J774 A1, J774A.1, J 774A.1, J774 A.1

Cross References: BTO:BTO_0000804, CLO:CLO_0006982, CLO:CLO_0007005, EFO:EFO_0022735, MCCL:MCC:0000252, CLDB:cl2924, CLDB:cl2925, CLDB:cl2926, CLDB:cl2927, CLDB:cl2928, CLDB:cl4914, ATCC:TIB-67, BCRC:60140, BCRJ:0121, CCRID:1101MOU-PUMC000222, CCRID:1102MOU-NIFDC00043, CCRID:4201MOU-CCTCC00176, CCTCC:GDC0176, ChEMBL-Cells:ChEMBL3307516, ChEMBL-Targets:ChEMBL614040, CLS:400220, DSMZ:ACC-170, DSMZCellDive:ACC-170, ECACC:91051511, ICLC:ATL98011, IZSLER:BS TCL 83, JCRB:IFO50023, JCRB:JCRB9108, KCB:KCB 2010167, KCLB:40067, Lonza:645, NCBI_Iran:C483, PubChem_Cell_line:CVCL_0358, Wikidata:Q54898489

ID: CVCL_0358

Vendor: CLS

Catalog Number: 400220

Hierarchy: cvcl_4692

Record Creation Time: 20220624T070937+0000

Record Last Update: 20260816T000335+0000

Ratings and Alerts

No rating or validation information has been found for J774A1.

Warning: Discontinued: JCRB; IFO50023

Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 190 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Desveaux JM, et al. (2026) Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of *Pseudomonas aeruginosa* act through distinct mechanisms. *eLife*, 14.

Rahaman S, et al. (2026) Protocol for quantifying silent ribosome induction in yeast and mammalian cells using polysome profiling. *STAR protocols*, 7(2), 104447.

Misra R, et al. (2026) Dengue protease-mediated activation and polarization of macrophages. *International journal of biological macromolecules*, 365, 152322.

Michail K, et al. (2026) Immunomodulatory Potential of Quinoline Q3, a Selective Inhibitor of the Canonical NF- κ B Pathway in Macrophages. *ChemMedChem*, 21(13), e70370.

Shi FL, et al. (2026) Luteolin mitigates inflammatory organ injury by targeting XIAP to block PANoptosis and mitochondrial dysfunction. *International immunopharmacology*, 173, 116271.

Corral J, et al. (2026) A novel GntR-ABC efflux system mediates oxidative stress response, drug resistance, motility and virulence in *Acinetobacter baumannii* ATCC 17978. *Frontiers in microbiology*, 17, 1748186.

Kalmantaeva OV, et al. (2026) Chimeric Antibody Engineering Against *Bacillus anthracis* Lethal Toxin: Neutralization Efficacy and Mechanism of Action. *Toxins*, 18(1).

- Elsbaey M, et al. (2026) Attenuation of LPS-induced inflammatory responses in J774A.1 macrophages by phenylpropanoids and ursane triterpenes from *Lavandula coronopifolia* Poir. *Scientific reports*, 16(1).
- Chen D, et al. (2026) Investigating the role of baseline gut *Akkermansia muciniphila* and its co-metabolite palmitoleic acid in BCG vaccine efficacy: a preclinical study. *EBioMedicine*, 130, 106404.
- Nam J, et al. (2026) Transdermal Delivery of an mRNA-Liposome Vaccine via Dissolving Microneedle to Preserve Vaccine Activity and Enhance Immune Activation. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(34), e22846.
- Li YF, et al. (2026) Two New Pyrrole Alkaloids From *Lanmaoa asiatica*. *Chemistry & biodiversity*, 23(2), e02700.
- Liu E, et al. (2026) Oral milk exosome-PLGA nanoparticles enhance anti-tuberculosis efficacy of PBTZ169 and bedaquiline. *iScience*, 29(5), 115641.
- Hsu AY, et al. (2025) Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution. *Cell*, 188(6), 1623.
- Chen X, et al. (2025) Glutamine limits NLRP3 inflammasome activation and pyroptosis in macrophages by sustaining the IRG1/itaconate axis. *The FEBS journal*.
- Saviano A, et al. (2025) PEPITEM, its tripeptide pharmacophores and their peptidomimetic analogues regulate the inflammatory response through parenteral and topical dosing in models of peritonitis and psoriasis. *Pharmacological research*, 213, 107624.
- Sun Y, et al. (2025) TRIF-TAK1 signaling suppresses caspase-8/3-mediated GSDMD/E activation and pyroptosis in influenza A virus-infected airway epithelial cells. *iScience*, 28(1), 111581.
- Xie Y, et al. (2025) Transposition of insertion sequence element from KPC plasmid enhances intracellular survival of *Klebsiella pneumoniae*. *EBioMedicine*, 120, 105944.
- Beielstein AC, et al. (2025) Protocol for assessing antibody-mediated cellular phagocytosis of lymphoma cells by human and murine macrophages in vitro. *STAR protocols*, 6(4), 104126.
- Li X, et al. (2025) Sudapyridine (WX-081) inhibits *Mycobacterium tuberculosis* by targeting ATP synthase and upregulating host innate immunity. *mSphere*, 10(6), e0014925.
- Ding N, et al. (2025) Engineered extracellular vesicles demonstrate altered endocytosis and biodistribution and have superior oral siRNA delivery efficiency compared to lipid nanoparticles. *International journal of pharmaceutics*: X, 10, 100428.